Fig. 5.

mDC are not necessary for priming of AML-specific CTL. a. mDC were treated with CVA21 or CVA21-treated ICAM-1/KG-1 cells for 48 h and expression of the activation markers, CD86, CD80 or HLA-DR, was examined (n = 4). b. ICAM-1/KG1-specific CTLs were primed with or without autologous mDC (±CVA21) and CTL-mediated lysis of relevant ICAM-1/KG-1 targets was measured by ⁵¹Cr release assay. Solid lines indicate CTL primed in the presence of mDC, dashed lines indicate CTL primed in the absence of mDC (n = 3). c. ICAM-1/KG1 CTLs, primed in the absence of mDC, were co-cultured with relevant (ICAM-1/KG-1) or irrelevant (Raji) target cells (n = 3) for 5 h and tumor specificity was examined using CD107a/b degranulation. Error bars indicate SEM. *denotes statistical significance